In cases where a PRO is not contained in the TMA and is not the primary endpoint (but is a reliable and valid pre-defined endpoint and is consistent with the primary endpoint), does the PRO need to be designated as a key secondary outcome in order to be included in promotional materials? Additionally, generally speaking, under what circumstances would the disclosure of other failed secondary endpoints be required?
G
GeoffLS20
@GeoffLS20
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.